Ibrutinib for anemia caused by immune destruction in CLL/SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years.
- You have CLL or SLL, or a CLL-like blood condition called MBL.
- You have active AIHA (immune anemia), meaning low hemoglobin plus lab signs of red blood cell breakdown, and a positive DAT test (a blood test showing antibody/complement on red cells).
- Your AIHA has returned after steroid treatment, or your anemia did not respond to steroids within about 3 weeks, or you need ongoing steroids at more than 10 mg per day to keep control.
- You cannot currently be taking any CLL/SLL- or AIHA-targeting treatment other than corticosteroids (steroids).
- You have not taken ibrutinib before for CLL treatment, and you are able to take ibrutinib (no serious liver impairment, no allergy, and you are not on warfarin or other vitamin K pills).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
This trial studies an approach for people with newly diagnosed CLL/SLL (chronic lymphocytic leukemia or related disease) who need treatment. It tests whether alternating two types of chemotherapy with ibrutinib (a targeted pill) can control the disease better and safely.
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.